Drug · DIN 02493543
IBRANCE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since September 21, 2020; first marketed September 21, 2020.
- Drug Identification Number (DIN)
- 02493543
- Company (DIN owner)
- Pfizer Canada UlcKirkland, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Palbociclib L01EF01
- Class
- Human
- Record last updated
- July 31, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| PALBOCICLIB | 100 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- October 31, 2019: NOC 22843Supplement to a New Drug Submission (SNDS) · Addition of tablet formulation
Other DINs named IBRANCE
- DIN 02493535 · Marketed
- DIN 02493551 · Marketed
- DIN 02453150 · Cancelled Post Market
- DIN 02453169 · Cancelled Post Market
- DIN 02453177 · Cancelled Post Market